Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bristol-Myers Squibb
Related studies linked through entity extraction aliases.
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
- Status
- UNKNOWN
- Phase
- PHASE2
A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants
- Status
- WITHDRAWN
- Phase
- PHASE1
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
- Status
- COMPLETED
- Phase
- PHASE2
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
- Status
- COMPLETED
- Phase
- PHASE2